Content

Is Tirzepatide Safe? What the Evidence Shows

Creator: Julian Reyes, Health Writer
Published: 2026-08-26

Safety is not a property of the molecule. It is the dose, the source of the vial, your own medical history, and whether a licensed clinician is accountable for the decision.

Julian Reyes, Health Writer August 26, 2026 7 min read

Two people sit talking in armchairs in a bright living room, one holding a mug

The short version

Tirzepatide carries a boxed warning for thyroid C-cell tumors seen in rats and is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or MEN 2.
A Scandinavian cohort of 145,410 people starting a GLP-1 receptor agonist found no substantially increased thyroid cancer risk over a mean 3.9 years (hazard ratio 0.93, 95% CI 0.66 to 1.31) — reassuring, but class-wide rather than tirzepatide-specific.
In the approved product's weight-reduction trials, acute pancreatitis occurred in 0.2% on tirzepatide and 0.2% on placebo; cholecystitis in 0.7% versus 0.2%. Across 76 trials and 103,371 patients, GLP-1 medicines raised gallbladder and biliary risk by a relative risk of 1.37.
GLP-1 medicines leave food in the stomach: 56% of users who had fasted normally still had increased gastric contents before anesthesia, against 19% of non-users, and pausing the drug longer did not help.
The longest randomized safety record is 176 weeks in SURMOUNT-1 with no new safety signals, plus a median four years in SURPASS-CVOT, where major cardiovascular events occurred in 12.2% on tirzepatide versus 13.1% on dulaglutide.
Through Promise, tirzepatide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved, and the FDA had logged more than 730 adverse event reports for compounded tirzepatide as of 31 May 2026.

Is tirzepatide safe? Not for everyone, and the exclusions are specific rather than vague. Tirzepatide carries a boxed warning for thyroid C-cell tumors seen in rats, and it is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2). It has documented associations with acute pancreatitis, gallbladder disease, low blood sugar alongside insulin or a sulfonylurea, and a stomach that has not emptied before anesthesia. For people screened out of those categories, the randomized safety record now runs to three years of continuous treatment.

Safety is not a property of a molecule. It is the molecule plus the dose, the source of the vial, your own history, and whether someone qualified is accountable. This page is about how that evidence was gathered and who applies it; the symptom-by-symptom list lives in tirzepatide side effects.

The boxed warning, in plain terms

In rats, tirzepatide caused thyroid C-cell tumors dose-dependently and duration-dependently, at exposures relevant to human dosing. That sits at the top of the approved brand-name product's prescribing information as a boxed warning, and the label states plainly that whether the same happens in people is unknown (Zepbound prescribing information, DailyMed). The consequence is a hard line: a personal or family history of MTC, or MEN 2, rules the drug out.

A Scandinavian cohort has since compared 145,410 people starting a GLP-1 receptor agonist with 291,667 starting a DPP-4 inhibitor and found no substantially increased thyroid cancer risk: hazard ratio 0.93 (95% CI 0.66 to 1.31) over a mean 3.9 years, with the medullary subtype at 1.19 (0.37 to 3.86) on very small case numbers (Pasternak et al., BMJ 2024). Two caveats travel with it: that covers the class rather than tirzepatide specifically, and 3.9 years is a follow-up window, not a lifetime. Reassuring is the right word; settled is not.

Is tirzepatide safe for everyone? Who it is not for

The screening questions are not decoration. Each maps to the label:

A personal or family history of MTC, or MEN 2. A contraindication, not a discussion.
Pregnancy. The label directs discontinuation once pregnancy is recognized.
Severe gastroparesis, where the labeling says the product is not recommended.
Insulin or a sulfonylurea already in the medication list — not an exclusion, but a reason to change those doses.
A history of pancreatitis or gallbladder disease, which shifts the prescriber's calculation.

A questionnaire that never asks these things is not screening you. It is processing an order.

Pancreatitis and gallbladder disease, with the actual rates

In the weight-reduction trials behind the approved product, acute pancreatitis occurred in 0.2% on tirzepatide and 0.2% on placebo. Gallbladder events were more lopsided: cholelithiasis 1.1% versus 1.0%, cholecystitis 0.7% versus 0.2%, cholecystectomy 0.2% versus none.

The class picture is larger. A meta-analysis of 76 randomized trials covering 103,371 patients associated GLP-1 receptor agonist treatment with gallbladder or biliary disease at a relative risk of 1.37 (95% CI 1.23 to 1.52), rising to 2.29 (1.64 to 3.18) in the weight-loss trials and increasing with higher doses and longer use (He et al., JAMA Internal Medicine 2022). Rapid weight loss is itself a gallstone risk factor, so the mechanism is not mysterious.

Against its nearest relative it looks similar. A new-user cohort study matched 46,620 pairs starting tirzepatide or semaglutide and reported a hazard ratio of 1.07 (0.90 to 1.26) for a composite of acute pancreatitis, biliary disease, bowel obstruction, gastroparesis and severe constipation (Crisafulli et al., Annals of Internal Medicine 2026). On severe gastrointestinal outcomes the two behave much alike.

Low blood sugar depends on what else you take

Tirzepatide's effect on insulin release is glucose-dependent, so on its own it rarely drives blood sugar below normal. The picture changes in combination: the label warns that concomitant use with insulin or an insulin secretagogue such as a sulfonylurea may increase the risk of hypoglycemia, including severe hypoglycemia, and that reducing the dose of those medicines may be necessary. That is why the intake asks for a complete medication list — and why tirzepatide dosage is set by a clinician rather than a chart.

Surgery, anesthesia and a stomach that has not emptied

Because these medications slow gastric emptying, a standard preoperative fast may not leave the stomach in the state the anesthesiologist assumes. In an ultrasound study of 124 patients who had fasted by the standard rules, increased residual gastric content was found in 56% of GLP-1 receptor agonist users against 19% of non-users — an adjusted prevalence ratio of 2.48 (95% CI 1.23 to 4.97) — and how long the drug had been paused made no measurable difference (adjusted odds ratio 0.86, 0.65 to 1.14) (Sen et al., JAMA Surgery 2024). The approved product's labeling now warns about pulmonary aspiration during general anesthesia or deep sedation. Anyone scheduling surgery, an endoscopy or a sedated dental procedure should tell that team about the medication well before the day.

What the long-term data covers, and what it does not

The longest randomized run is SURMOUNT-1, whose participants with obesity and prediabetes stayed on treatment for 176 weeks. Across those three years the most common adverse events remained gastrointestinal, mostly mild to moderate and concentrated in the first 20 weeks of dose escalation, and the investigators reported that no new safety signals were identified (Jastreboff et al., NEJM 2025).

The largest safety comparison is SURPASS-CVOT: 13,299 people with type 2 diabetes and cardiovascular disease randomized to tirzepatide or dulaglutide, followed a median of four years. Cardiovascular death, heart attack or stroke occurred in 12.2% versus 13.1% (hazard ratio 0.92, 95.3% CI 0.83 to 1.01), meeting noninferiority, with adverse events broadly similar and more gastrointestinal events on tirzepatide (Nicholls et al., NEJM 2025).

What does not exist is decades; the molecule was first approved in 2022. Tolerability is already measurable — in the original 72-week SURMOUNT-1 report, adverse events caused 4.3%, 7.1% and 6.2% of participants to stop at 5 mg, 10 mg and 15 mg against 2.6% on placebo — but genuinely rare events, and anything past roughly four years, are not characterized yet.

Is compounded tirzepatide safe? The distinction that matters

Through Promise, tirzepatide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. Compounded medications are not reviewed by the FDA for safety, effectiveness or quality.

That difference deserves specifics rather than a shrug. As of 31 May 2026 the FDA had received 990 adverse event reports for compounded semaglutide and more than 730 for compounded tirzepatide, while noting that state-licensed pharmacies need not report, so the real number is likely higher; most reported events resemble those seen with the approved versions (FDA, June 2026). It has separately flagged dosing errors from people measuring out of a vial for the first time and confusing milliliters, milligrams and "units", and shipments arriving warm.

Regulatory status is one input into a prescribing decision rather than the whole of it: a licensed provider may still prescribe a compounded formulation where they judge it appropriate, and that decision is between you and your doctor. What compounded tirzepatide actually involves is worth reading first.

What accountability looks like in practice

Most of the safety in this category is produced before anyone injects anything. The intake works through the list above and adds kidney function, other GLP-1 medications in use, and any upcoming procedure under anesthesia. Each answer moves the decision, and some answers stop it.

The rest is what happens afterwards. A dispensed prescription has a named pharmacy behind it, a record of what was made, a dose someone qualified chose, and a clinician to contact when something feels wrong at week three. An anonymous vial has none of that. How to get tirzepatide prescribed walks through the route.

A licensed provider in Promise's prescriber network reviews every request and prescribes only when tirzepatide is appropriate for the person asking. Not everyone qualifies, and being declined is a real answer to the question this article asks.

Common questions

Is tirzepatide safe?

For people who pass screening, the randomized safety record is substantial: three years of continuous treatment in SURMOUNT-1 with no new safety signals, and a four-year cardiovascular outcomes trial in 13,165 patients. It is not safe for everyone. A personal or family history of medullary thyroid carcinoma or MEN 2 rules it out, and pancreatitis, gallbladder disease and low blood sugar in combination with insulin are known risks.

Who should not take tirzepatide?

Anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, and anyone with known serious hypersensitivity to tirzepatide or its excipients. The labeling also says it is not recommended in severe gastroparesis, and directs discontinuation when pregnancy is recognized. A history of pancreatitis or gallbladder disease, and current insulin or sulfonylurea use, change what a prescriber decides.

Is compounded tirzepatide FDA-approved?

No. FDA-approved versions of tirzepatide exist, but the compounded formulations offered here are not FDA-approved, and compounded medications are not reviewed by the agency for safety, effectiveness or quality. A licensed provider may still prescribe a compounded formulation where they judge it appropriate — that decision sits with you and your doctor.

Does tirzepatide cause thyroid cancer?

That is unknown in people. The boxed warning comes from rats, where tirzepatide caused dose-dependent and duration-dependent thyroid C-cell tumors. A Scandinavian cohort of 145,410 people starting a GLP-1 receptor agonist found no substantially increased thyroid cancer risk over a mean 3.9 years (hazard ratio 0.93). That study covered the class rather than tirzepatide specifically, and the contraindication stands.

Do I need to stop tirzepatide before surgery?

That is a decision for the surgical and anesthesia team, and they need to know you take it. A gastric ultrasound study found increased residual stomach contents in 56% of GLP-1 users who had fasted normally versus 19% of non-users, and pausing the drug longer did not measurably help. The approved product's labeling now warns about pulmonary aspiration under general anesthesia or deep sedation.

Is tirzepatide safe long term?

The longest randomized evidence runs to 176 weeks in SURMOUNT-1, where investigators reported no new safety signals, plus a median of four years in the SURPASS-CVOT cardiovascular trial. Beyond roughly four years there is no controlled data, because the molecule was first approved in 2022. Rare events and very long-term effects are not characterized yet.